SPTX (Seaport Therapeutics) Long-Term Debt: $0.00 Mil (As of Dec. 2025)


SPTX Seaport Therapeutics Inc SPTX
11 GF Score
Price $21.43
! 1 Warning Sign
View Full Analysis

What is Seaport Therapeutics Long-Term Debt?

Seaport Therapeutics SPTX +10.37% 11 Long-Term Debt is $0.00 Mil as of Dec. 2025. GuruFocus rates SPTX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Seaport Therapeutics's Long-Term Debt for the quarter that ended in Dec. 2025 was $0.00 Mil.

Seaport Therapeutics  (NAS:SPTX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Seaport Therapeutics Long-Term Debt Related Terms

Seaport Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Seaport Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seaport Therapeutics Long-Term Debt Chart

Seaport Therapeutics Annual Data
Trend Dec24 Dec25
Long-Term Debt
0.00 0.00

Seaport Therapeutics Semi-Annual Data
Dec24 Dec25
Long-Term Debt 0.00 0.00
SPTX
11GF Score
Seaport Therapeutics Inc SPTX
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Seaport Therapeutics (SPTX) has a Long-Term Debt of $0.00 Mil as of Dec. 2025.
Is Seaport Therapeutics' Long-Term Debt too high?
Seaport Therapeutics' current Long-Term Debt is $0.00 Mil. Overall, Seaport Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Seaport Therapeutics' Long-Term Debt compare to LXRX and DRTS?
Seaport Therapeutics' Long-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Seaport Therapeutics's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seaport Therapeutics stock overvalued right now?
Seaport Therapeutics (SPTX) has a current Long-Term Debt of $0.00 Mil. The current Long-Term Debt is $0.00 Mil. Seaport Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Seaport Therapeutics (SPTX), the current Long-Term Debt is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seaport Therapeutics Business Description

Address 101 Seaport Boulevard, Floor 12, Boston, MA, USA, 02210
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
11GF Score

Get the complete analysis for SPTX

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.43
Price